Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Mechanistically NAergic signaling in the VTA modulates neuro
2024-04-07

Mechanistically, NAergic signaling in the VTA modulates neuronal activity presumably via α1-AR. The majority of α1-ARs are found in the VTA are located presynaptically on unmyelinated phalloidin and axon terminals of glutamatergic and GABAergic neurons. However, α1-ARs are also found on neuronal de
-
The extent to which GPCR oligomerization
2024-04-07

The extent to which GPCR oligomerization is a regulated process still remains unclear. Reported effects of ligands on both GPCR homo- and heteromers are highly variable and depend on GPCR subtypes and the specific ligand used. According to our data, chronic treatment of mice with both paroxetine or
-
We aim to evaluate the AK
2024-04-07

We aim to evaluate the AK in regulating adenosine signaling in the retina. It was reported that the degree of phenanthroline injury directly depends on expression levels of AK and the resulting extracellular levels of adenosine (Boison, 2006). Indeed, transgenic mice overexpressing AK are highly su
-
MRS1523 False positivity of Anti AChR
2024-04-03

False positivity of Anti-AChR Ab titers, due to cross reactivity with bungarotoxin, has previously been demonstrated. One such study reported that patients with amyotrophic lateral sclerosis, who had received long term snake venom therapy, had developed antibodies to bungarotoxin and hence demonstr
-
br Discussion The clinical course of our patient
2024-04-03

Discussion The clinical course of our patient until May 2012 was rather typical of early onset AChR-MG. Later on, the pattern of the disease was more typical of MuSK-MG, as evidenced by the distribution of myasthenic weakness and the unprovoked exacerbations. The protease inhibitor of MuSK-MG ap
-
Osteoblasts have been thought to be the major
2024-04-03

Osteoblasts have been thought to be the major cell type that expresses RANKL (Suda et al., 1999) which is a ligand for osteoprotegerin (OPG) and which functions as a key factor for osteoclast differentiation and activation. Recently, Nakashima and his colleagues (Nakashima et al., 2011) demonstrated
-
Our study like that of Zill et
2024-04-03

Our study, like that of Zill et al. (2012) included European Caucasians, although their population was much smaller (n=162) and more heterogeneous (19–72years). Further, potential confounding or effect modification by other health, lifestyle or genetic factors was not considered. These differences m
-
chemokine receptor antagonist Based on the observation that
2024-04-03

Based on the observation that antipsychotic drugs increase 5-HT1A–D2 heteromerization level (Łukasiewicz et al., 2016), we set out to compare the effect of paroxetine to that of risperidone. Paroxetine, a potent SSRI, is very effective in the treatment of depression and anxiety disorders, e.g., gene
-
br Aromatase inhibitors The aromatase
2024-04-03

Aromatase inhibitors The aromatase enzyme, P450arom, belongs to the super-family of P450 proteins which includes more than 480 members divided in 74 different families. P450arom is a unique member of family 19 [39], and is located in the endoplasmic reticulum of mammalian EGTA that express the C
-
The physiologic conditions and signaling mechanisms that reg
2024-04-03

The physiologic conditions and signaling mechanisms that regulate apelin secretion and APLNR expression in malignant tissues appear to be multifactorial. Previous studies have shown that hyperplastic and neoplastic cholangiocytes secrete a variety of hormones, peptides, and growth factors that help
-
The basis for the protonation of chitosan is the alkaline
2024-04-03

The basis for the protonation of chitosan is the alkaline primary amino group, which is also the reason for the special properties of chitosan (Guibal, Van Vooren, Dempsey, & Roussy, 2006; Tamer et al., 2017; Yang et al., 2014). Our previous work (Meng et al., 2012) and several other reports (Yan et
-
Similar studies in Swedish Mutation
2024-04-03

Similar studies in Swedish Mutation of APP AD transgenic mice revealed reduced dynamin 1, AP180, and synaptophysin expression in the hippocampus, particularly prominent in the CA1 and CA4 subfields [19]. These findings imply that Aβ can act not only as a modulator of exocytosis but is a potent regul
-
Aldose reductase AR is an NADPH
2024-04-02

Aldose reductase (AR), is an NADPH-dependent aldo-keto reductase very well studied as a catalyst of glucose conversion to sorbitol in the polyol pathway [11], [12]. In the diabetic lens characterized by chronically high levels of glucose, AR is responsible for production of high levels of sorbitol a
-
Application of the broad acting HTR
2024-04-02

Application of the broad-acting 5-HTR antagonist methiothepin (Bard et al., 1996, Hoyer et al., 1994, Peroutka, 1990) converted the TBS-induced response of both thalamocortical and intracortical A1 synapses from LTP to LTD, an effect that was mimicked by the selective 5-HT2R antagonist ketanserin (L
-
br Therapeutic advantages and clinical implications
2024-04-02

Therapeutic advantages and clinical implications of caffeine treatment in ROP The demonstration of the role of the adenosine receptor in development of ROP and protection by caffeine suggests two potential therapeutic strategies with high translational potential: a) modification of caffeine treat
15561 records 184/1038 page Previous Next First page 上5页 181182183184185 下5页 Last page